Looking ahead to the potential implications of Biogen’s (Nasdaq: BIIB) landmark approval in Alzheimer’s (AD), industry analyst GlobalData has conducted research into the market potential for a next-generation candidate.
Developed by Swiss company Roche (ROG: SIX), gantenerumab is another anti-amyloid therapy, a monoclonal antibody, and potentially the first subcutaneously administered option.
The treatment has been awarded Breakthrough Therapy designation from the US regulator, and GlobalData said a 2024 launch could result in revenues of over $2 billion by 2030, across developed markets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze